Restarting Zopiclone After 2-Month Discontinuation in a 64-Year-Old with ICD
Yes, it is generally safe to restart zopiclone in this patient, though careful monitoring is warranted given the cardiac device and age. The available evidence does not identify specific contraindications to zopiclone use in patients with ICDs, and the drug has demonstrated acceptable safety profiles in older adults.
Key Safety Considerations
Cardiac Device Compatibility
None of the major cardiac device guidelines 1, 2, 3, 4 identify hypnotic medications like zopiclone as contraindicated in patients with ICDs. The ICD guidelines focus primarily on antiarrhythmic drugs, electrolyte management, and device programming—not sedative-hypnotics. There is no evidence that zopiclone interferes with ICD function or increases arrhythmic risk.
Age-Related Factors
At 64 years old, this patient falls into the older adult category where zopiclone pharmacokinetics show some changes. The drug label 5 indicates that patients ≥65 years have a 41% increase in total exposure (AUC) and slightly prolonged elimination (t½ approximately 9 hours vs 6 hours). However, the recommended starting dose of 1-2 mg for elderly patients addresses this concern, and your patient at 64 is just below the threshold where mandatory dose reduction applies.
Long-Term Use History
The 20+ years of prior use is actually reassuring in several ways:
- Tolerance established: The patient has demonstrated long-term tolerability without apparent major adverse effects
- No withdrawal issues noted: The 2-month discontinuation period has passed without documented problems
- Known response: You have historical data on efficacy and side effects for this specific patient
Research evidence 6 shows that withdrawal from long-term zopiclone use can improve sleep quality in some patients, but this doesn't preclude restarting if insomnia has returned and is affecting quality of life.
Practical Restart Protocol
Dosing Strategy
Start with 3.75 mg (half tablet) for the first week, then increase to 7.5 mg if needed and well-tolerated. This conservative approach:
- Accounts for potential loss of tolerance during the 2-month break
- Minimizes risk of excessive sedation or falls
- Allows assessment of current efficacy needs
Monitoring Parameters
Watch specifically for:
- Daytime sedation or cognitive impairment (particularly important given ICD patients may need to recognize symptoms of arrhythmias)
- Falls risk (could lead to device lead dislodgement, though rare)
- Bitter taste (most common side effect, reported in <10% 5)
- Memory complaints (occurred in 1.3% in 6-month trials 5)
Duration Considerations
The drug label 5 and clinical evidence 7, 8 recommend short-term use (≤4 weeks). However, given this patient's 20+ year history, a pragmatic approach would be intermittent use (3-4 nights per week) rather than nightly, which may reduce tolerance development and dependence risk while maintaining efficacy.
Evidence Quality Assessment
The available evidence has important limitations:
- No specific studies examine zopiclone in ICD patients
- Most efficacy data 9, 10, 8 come from short-term trials (2-4 weeks)
- Long-term safety data 7 are primarily from postmarketing surveillance rather than controlled trials
- The systematic review 10 rated most studies as "low or unclear" quality
However, 15 years of clinical use with over 2.5 billion units dispensed 7 provides substantial real-world safety data showing low rates of serious adverse events.
Common Pitfalls to Avoid
- Don't assume the previous dose is still appropriate: Start lower after a 2-month break
- Don't ignore drug interactions: Check current medications, particularly CYP3A4 inhibitors which can increase zopiclone levels 2.2-fold 5
- Don't take with high-fat meals: This delays onset by ~1 hour and reduces peak concentration 5
- Don't combine with other CNS depressants without dose adjustment
- Don't forget to counsel about driving: Effects can persist into the next morning, particularly at higher doses
Alternative Consideration
If insomnia is related to ICD shocks or anxiety about cardiac events, addressing the underlying cardiac or psychological issues may be more appropriate than simply restarting hypnotics. Consider whether the patient needs ICD programming optimization, antiarrhythmic medication adjustment, or cognitive-behavioral therapy for insomnia (CBT-I) as adjunctive or alternative approaches.
The presence of an ICD is not a contraindication to zopiclone use, and restarting after a 2-month break is reasonable if insomnia is significantly affecting quality of life and other approaches have been inadequate.